F2G

Executive Summary

F2G is a UK-based biopharmaceutical company dedicated to developing novel therapies for life-threatening fungal infections, with a focus on first-in-class small molecules. The company leverages deep expertise in fungal genomics and biochemistry to address high unmet medical need in rare and severe fungal diseases, particularly among immunocompromised patients. F2G's lead candidate, olorofim (formerly F901318), is a novel oral antifungal targeting Aspergillus species and other resistant molds, representing a potential breakthrough in a field with limited treatment options. The drug has demonstrated promising efficacy and safety in Phase 2 trials and is currently undergoing a pivotal Phase 3 study (OASIS) for invasive aspergillosis. With a patient-first ethos and a clear focus on defined vulnerable populations, F2G is positioned to address critical gaps in antifungal therapy.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 OASIS trial topline results for olorofim in invasive aspergillosis75% success
• Q2 2027Regulatory submission (NDA/MAA) for olorofim to FDA and/or EMA65% success
• Q3 2026Strategic partnership or licensing deal for olorofim ex-UK/EU rights50% success